Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »

For full access to this article login to GEN Select now.

July 02, 2014

The Name Game: The Debate over Naming Follow-On Biologics

Should biosimilars have the same nonproprietary name as their reference products?

The Name Game: The Debate over Naming Follow-On Biologics

Eight of the top 10 bestselling drug products are expected to be biologics by 2016. [© Burlingham - Fotolia.com]

There is an ongoing debate over whether biosimilars and interchangeable biologics should share the same nonproprietary name as their reference biologics As patents covering biologics expire, companies other than the original manufacturers will seek to market their own versions of the originators’ biologics as biosimilars, “bio-betters,” or interchangeable biologics The ...

Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.

Get GEN Select Access Now

    • Do not put any letters or characters here if you are not a spy program.

Related content